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Abstract
Background: Cervical cancer, a preventable disease, is the third leading cause of cancer morbidity and mortality in
the Lao People’s Democratic Republic (Lao PDR). Since many cervical cancers are linked to human papilloma virus
(HPV) infection, vaccination against this virus may lead to a reduction in these types of cancer. The study described
here is the first to compare the cost-effectiveness of different HPV vaccination options in Lao PDR.
Methods: A dynamic compartment model was created. The model included routine screening activities already in
place, as well as theoretical interventions that included a 10-year old girl-only vaccination programme combined
with/without a 10-year old boy vaccination programme and/or a catch-up component. The simulation was run
over 100 years. In base case analyses, we assumed 70 % vaccination coverage with lifelong protection and 100 %
efficacy against HPV types 16/18. The outcomes of interest were the incremental cost per Disability-Adjusted Life
Year (DALY) averted.
Results: In base case analyses, according to the WHO definition of cost-effectiveness thresholds, vaccinating
10-year-old girls was very cost-effective. Adding a catch-up vaccination element for females aged 11–25 years
was also very cost-effective, costing 1559 international dollars (I$) per DALY averted. Increasing the age limit of
the catch-up vaccination component to 75 years old showed that this remained a cost-effective option (I$ 5840 per
DALY averted). Adding a vaccination programme for 10-year-old boys was not found to be cost-effective unless a short
time simulation (30 years or less) was considered, along with a catch-up vaccination component for both males
and females.
Conclusions: Adding a catch-up female vaccination component is more attractive than adding a 10-year-old boy
vaccination component.
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Background
Cervical cancer is the third leading cause of cancer
deaths among women in Lao People’s Democratic Re-
public (Lao PDR), with an estimated crude incidence
and mortality rates of 9.8 and 5.3 per 100,000 women
annually [1]. The vast majority of cervical cancers are
caused by infection with human papillomaviruses
(HPV), particularly HPV types 16 and 18. The high fa-
tality rate associated with cervical cancer in Lao PDR is
probably due to various factors. This includes the lack
of a national HPV vaccination programme, lack of ef-
fective chemo/radiotherapy in the country, and delays
in diagnosis [1]. The delay in diagnosis is in great part
due to the fact that there is no national cervical cancer-
screening programme in Lao PDR, where it has been esti-
mated that only 5 % of females aged 18–69 in urban areas
and 1 % in rural areas are screened every 3 years [1].
A systematic screening programme might reduce the
disease burden, but may not be possible in Lao PDR due
to various reasons including financial and sociocultural
barriers, poor healthcare infrastructure, and poor per-
formance of laboratory tests [2]. Given these problems,
HPV vaccination might be a more suitable approach for
the country. It has been shown to be efficacious, with
bivalent and quadrivalent vaccines providing extremely
high rates of protection against high grade cervical
intraepithelial neoplasia (CIN 2/3) related to HPV
types 16 and 18 [3]. Moreover, Goldie and colleagues
[4] showed that HPV vaccination in preadolescent fe-
males is very cost-effective in 72 Global Alliance for
Vaccines and Immunization (GAVI)-eligible countries,
including Lao PDR, and Jit and colleagues [5] found
similar outcomes on a global scale. However, no na-
tionwide vaccination strategy has so far been imple-
mented in Lao PDR.
A HPV vaccination pilot project, which consists of
vaccinating 5th grade schoolgirls (10–13 years old) in the
Lao capital Vientiane, and in neighbouring Vientiane
Province, is currently taking place. It is likely that such a
HPV vaccination programme will become routine prac-
tice in the future. However, vaccination coverage might
be low. Considering this eventuality, the authors thought
it is important to evaluate the benefit of complementing
such a vaccination programme with additional interven-
tions, such as adding a catch up vaccination campaign
and/or a 10-year-old boy vaccination element. In order
to examine these questions, we used a mathematical
modelling approach to estimate the cost-effectiveness of
various HPV vaccination strategies in the Lao context.
Methods
Model structure
Inspired by previous economic models of HPV vaccin-
ation [6], a compartmental dynamic population-based
model was created to reflect the expected effect of
HPV vaccination programmes, both in females and
males. The model considered whether the HPV geno-
types were 16, 18 or other high-risk type, or a low-risk
type. (Full methodological details are provided in the
Additional file 1).
For females, the model considered that an infection
with HPV regresses due to natural immunity, while
remaining susceptible to infection with other HPV types.
HPV infection may persist or progress into a cervical
intraepithelial neoplasia (low-grade CIN or high-grade
CIN). A low-grade CIN might regress to an immunity
state or an infection state, or progress into a high-grade
CIN. A high-grade CIN might regress to an immunity
state or an infection state or low-grade CIN, or might
progress into an invasive cervical cancer (local, regional
or distant, respectively). Women diagnosed with a high-
grade CIN are treated. Women with invasive cervical
cancer might be symptomatically detected. Diagnosed
cancer cases are treated, with a probability of recovery,
treatment failure or death (Fig. 1).
For males, only the susceptibility, infection and recov-
ery states were considered. Vaccinated people remained
susceptible for non-vaccine HPV types.
Parameters
Monthly age-specific transition probabilities from one
lesion state to another and regression rates presented in
Table 1 were taken from Kim and colleagues [7], while
infection rates were calculated by multiplying the sexual
relationship matrix by HPV genotype-specific transmissi-
bility and age-specific HPV prevalence in the opposite
sex. To simplify the model, we considered all members
of the population to be heterosexual. The sexual rela-
tionship matrix consisted of the monthly age-specific
probability of having a new sexual partner, in which each
age group has the probability of having sexual inter-
course with someone of the same and a different age
group of 0.6 and 0.4 respectively [8] (See Additional
file 1). The initial age of sexual intercourse was taken
to be 15 years old or more in both females and males
[9]. The screening and treatment parameters are also
described in the Additional file 1.
Model calibration
The population was stratified by gender and age. The
model is in the form of a realistic age structured (RAS)
model. The equations were numerically solved in
Berkeley Madonna version 8.3.18 [10]. The model was
calibrated using maximum likelihood. The details are de-
scribed in the Additional file 1. Briefly, the model was
first calibrated in order to produce a demographic struc-
ture similar to the 2014 distribution of the Vientiane
Capital province population (in one-year intervals) [11].
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Thereafter, the model was calibrated for the age-specific
incidences and mortalities of cervical cancer, according
to the Globocan estimates [1].
Scenarios
The baseline model considered that in Lao PDR there
is no vaccination program, and that the coverage of
routine cytology screening is 5.2 % among females aged
18–68 [1]. We assumed that screening coverage would
remain the same over time. The HPV vaccination pro-
grammes investigated consisted of a 10-year-old girl
vaccination programme alone, or combined with a
catch-up component and/or a 10-year-old boy vaccin-
ation element. The details of the strategies are sum-
marised in Table 2. The population of 10-year-old girls
was chosen because the current HPV vaccination pilot
project targets 5th grade female students who are
mostly 10 years old. The first selected age group for a
catch-up vaccination in females was 11–25 year-olds, as
this age group represents female undergraduate students
who are reachable through school and university-based in-
terventions. The 11–75 year-old age group represents the
population at risk of HPV infection in our model.
The coverage of HPV vaccination was assumed to be
about 70 % (30–80 %), with 100 % (30–100 %) effective-
ness against HPV type 16 and 18 and a lifelong protec-
tion (10 years to lifelong).
Costing
The perspective considered was essentially that of the
public healthcare system. Only direct medical costs and
the programmatic cost of the vaccination programme
itself were considered. The costing methodology is de-
tailed in the Additional file 1. Briefly, the cost of deliv-
ering HPV vaccines consisted of the price of the
vaccine and the programmatic cost of vaccination deliv-
ery. The programmatic cost of a three-dose HPV vac-
cine per individual was retrieved from an evaluation on
HPV vaccination performed in Vientiane by the WHO
(Phanmanysone Philakong, personal communication).
The Global Alliance for Vaccines and Immunization
(GAVI) vaccine cost per dose was used [12]. Medical
costs were estimated based on data from a cost study
done by the Lao PDR Ministry of Health (Maytry
Senchanthixay, personal communication). This included
cytology screening, visits & examinations, laboratory tests,
and treatments for precancerous lesions and cervical
Fig. 1 Model structure for the natural history of human papillomavirus infection and cervical cancer. The model structure reflects the natural
history of HPV infection towards cervical cancer. Women can be infected by HPV and progress to low-grade CIN or high-grade CIN, or regress
with natural immunity. Low-grade CIN progress to high-grade CIN, or regress thanks to the natural immunity. High-grade CIN progress to invasive
cervical cancer (local, regional and distant cancer), or regress thanks to the natural immunity. In the male model, there are three compartments
considered: susceptibility to infection, infection and recovery with natural immunity. Female can be protected by HPV vaccine
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Table 1 Summary of input parameters for the model
Parameters Baseline valuesa Rangeb Source
Progression
Healthy to infectionc HPV-16 0.000175–0.003148 0.0001426–0.00761 Calibrated
HPV-18 0.0004–0.000789 0.000102–0.00168
Other HR HPV 0.000206–0.004038 0.0001703–0.00911
LR HPV 0.000958–0.018412 0.00069–0.0537




Proportion (%) of women who transition
directly from HPV DNA to CIN2,3








CIN 2,3 to local cancer HR-16 HPV 0.000151–0.00906 [7]
HR-18 HPV 0.000264–0.01584
HR-other HPV 0.000199–0.01194
Local to regional invasive cancer 0.0200 [7]
Regional to distant invasive cancer 0.0250
Regression













Immunity (%) (HR-HPV types only)g HR-16 HPV 0.66 [7]
HR-18 HPV 0.86
HR-other HPV 0.59
Annual probability of symptom detectionh Local invasive cancer 0.33 [7]
Regional invasive cancer 0.60
Distant cancer 0.9
Proportion of cancer patient receiving
the treatment
Local cancer 100 % Calibrated
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cancer. The cost of treatment for stage-specific invasive
cervical cancer was obtained from Goldie and colleague
[4]. Unit prices are reported in the value of 2013 inter-
national dollars (I$), using purchasing power parity
(PPP).
Analyses
The simulation process was run deterministically over
a 100-year span to capture the long-term benefits of
vaccination. For each option, the output consisted of
the cumulative number of cervical cancers per 1000
women, the Disability-adjusted life years (DALYs) per
1000 women, and the cost of screening and treatment
per 1000 women. The strategies were ranked based on
their cost, from lowest to highest. In the case of a
non-dominant situation, strong, or extended domin-
ance, the incremental cost-effectiveness ratio (ICER)
was calculated using the reduction of HPV type 16/18-
related cervical cancer cases and DALYs averted as
denominators. DALYs were calculated based on the
Global Burden of Disease, using standard life expect-
ancy, without age weighting [13]. The disability
weighting for cancer treatment was retrieved from
current literature [14]. All costs and DALYs were dis-
counted at a rate of 3 % in the base case simulations
[15]. The cost-effectiveness results were organised into
three categories: 1) very cost-effective (ICER < 1 Lao
gross domestic product (GDP) per capita; 2) cost-
effective (ICER between 1 and 3 times the GDP per
capita); and 3) not cost-effective (ICER > 3 times the
GDP per capita) [16]. One-way sensitivity analyses
were conducted to identify the parameters, according
to the literature and assumption, that might influence the
incremental cost-effectiveness ratio per DALY averted.
Table 1 Summary of input parameters for the model (Continued)
Regional cancer 80 %
Distant cancer 70 %
Age-specific 5-year survival proportion
after diagnosis and treatment (%)i
Local cancer 0.29–71 % Calibrated
Regional cancer 0.24–78 %








aBaseline values are monthly age-specific rates, unless otherwise noted
bRange is age-specific rate calibrated with the assumption of unchanged natural progression and regression of HPV infection and cervical cancer
cThe transition from healthy state to infection is a force of infection derived from the number of sexual partner change, HPV type-specific transmissibility
(range: 0.353–0.41)
dHPV human papillomavirus, CIN cervical intraepithelial neoplasia, HR high risk, LR low risk
e70 % of women with CIN 1 regress to normal, 30 % to HPV
f70 % of women with CIN2,3 regress to normal, 15 % to HPV, 15 % to CIN 1
gImmunity represents the degree to protection each woman faces against future type-specific infection after infection after first infection and clearance. The immunity
was assumed to be lifelong protection
hThe annual probability of symptom detection corresponds to 15 % for local cancer and 85 % for advanced cancer
iAge-specific survival proportion was calibrate, based on a mortality rate by Globocan [1]
Table 2 Summary of the vaccination strategies evaluated
Female Male
Routine vaccination Catch up campaign Routine vaccination Catch up campaign




4 X X X
5 X X X X
6 X X
7 X X X
8 X X X X
Note: Routine vaccination is to give HPV vaccine to a 10-year-old girl and/or boy every year
Catch-up campaign is one-year catch-up HPV vaccination for females and/or male aged 11-25 years or 11-75 years
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Results
Model calibration
The model was able to reproduce the expected values
regarding demographic data in 2014 for Vientiane
Capital, for both female and male populations (Additional
file 1). However, the number of individuals was high for
those aged 10–25 years compared with expected values,
while it was low for those aged 25–35 years old. The
model reproduced results for the estimated incidence of
cervical cancer and its mortality due to any high-risk HPV
type that were consistent with the estimates of Globo-
can, 2012 (Fig. 2). The proportion of cervical cancers
related to HPV types 16 and 18 was about 75 %.
Clinical impact and cost-effectiveness
The model shows that vaccinating 10-year-old girls has
the potential to reduce the number of cervical cancers
due to HPV type 16/18 by 78 % and provides a potential
diminution of 31 DALYs per 1000 women (Table 3). Fur-
thermore, the model predicts that these benefits increase
when a catch-up vaccination and/or a 10-year-old boy
vaccination component are added. The reduction of can-
cer in adding catch-up vaccination was in earlier stage
compared to adding boy vaccination (Fig. 3).
In terms of cost, the baseline strategy (no vaccination
with 5.2 % coverage of conventional cytology screening)
is the cheapest option, followed by a 10-year-old girl
vaccination programme and a catch-up vaccination com-
ponent for 11–25 year-old females, respectively. In terms
of ICER per cancer prevented, the female vaccination
option is cost-effective, with an ICER of I$ 6334 per can-
cer prevented, which is between 1 and 3 GDP per capita.
Adding a catch-up vaccination component for females
aged 11–25 years old, or a boy vaccination component
to the girl vaccination programme does not appear to be
cost-effective since their ICERs are higher than 3 GDP
per capita. Other strategies are dominated by adding
catch-up component for 11–75 year-old females. In
terms of ICER per DALY averted, compared to the base-
line, the model shows that the girl vaccination option is
very cost-effective. Adding a catch-up vaccination com-
ponent for 11–25 year-old females is very cost-effective
compared to the girl vaccination option alone. Moreover,
extending the age limit of the catch-up component up
to 75 years is also cost-effective. In contrast, adding a
boy vaccination component to the girl vaccination op-
tion alone, or along with a catch-up component, does
not appear to be cost-effective (Table 3).
Table 4 shows the model output results when varying
the upper ages for the catch-up component in females.
The addition of a catch-up component remains very
cost-effective until an upper age of 40 years.
Sensitivity analyses
Sensitivity analyses show that the parameters that have
the greatest impact on ICERs per DALY averted are vac-
cination coverage, cost of vaccine, discount rate, inci-
dence of cervical cancer, duration of vaccine protection
and of natural immunity, and efficacy of the vaccine.
The cost of cancer treatment and the disability weight-
ing had no impact on ICERs.
The girl vaccination program is robust to changes in
vaccination costs. But the ICER for a catch-up compo-
nent for 11–25 year olds is higher than one GDP per
capita when the cost of the vaccine is I$ 50 or higher
per dose. Meanwhile, the model predicts that adding a
catch-up vaccination component for females aged 11–
75 years old becomes very cost-effective compared to a
catch-up for females aged 11–25 years old in the fol-
lowing situations: 1) vaccination coverage is 50 % or
lower, 2) vaccine effectiveness is 30 % or lower, 3) the
incidence of cervical cancer increases to 40 %, 4) the
duration of natural immunity and of vaccine protection
Fig. 2 Model calibration to age-specific incidence and mortality of cervical cancer. Predicted incidence of cervical cancer and predicted mortality
related to cervical cancer follow the age specific-distribution of observed data in Lao PDR, as estimated by Glocoban
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Table 3 The effectiveness, total cost, and incremental cost-effectiveness by vaccination strategy against cervical cancer due to HPV
types 16 and 18






















1. No vaccination with
current screening
4497 3.4 - - - - - -
2. 10 years old girls 21,599 0.7 77.9 31.1 8000 695 6334 550
3. 10 years old girls + catch-
up girls aged 11–25 years
old
27,807 0.4 86.8 35.1 9269 792 20,693 1559
4. 10 years old girls + boys 38,030 0.6 81.3 32.6 13,582 1167 D D
5. 10 years old girls + catch-
up girls aged 11–75 years
old
39,059 0.3 91.4 37.0 12,600 1056 112,520 5840
6. 10 years old girls + boys
+ catch-up girls aged
11–25 years old
44,263 0.4 87.4 35.3 14,754 1254 D D
7. 10 years old girls + boys
+ catch-up girls and boys
aged 11–25 years old
50,210 0.4 88.7 35.9 16,737 1399 D D
8. 10 years old girls + boys
+ catch-up girls aged
11–75 years old
55,520 0.3 91.4 37.0 17,910 1501 D D
9. 10 years old girls + boys
+ catch-up girls and boys
aged 11–75 years old
72,723 0.3 91.8 37.2 23,459 1955 D 168,320
Note: The cost-effectiveness ratio was a comparison of an option and the baseline scenarios (no vaccination with current screening). The incremental cost of
effectiveness ratio expressed as cancer prevented or DALY averted is listed in order of increasing cost. In non-dominant strategy, the ICER was calculated by
devising different cost to different effectiveness. ICERs is comparing the option to the next best alternative option. The D refers to strong dominance, which is
expressed as higher cost, but lower effectiveness than alternative options. The currency is 2013 international dollars, using purchasing power parity
The GDP per capita in 2013 was about 4822 international dollars [30]
Fig. 3 Change over time the total number of cervical cancer related to HPV type 16 and 18. The number of cervical cancer decreases over time
in the strategies to, either adding boy or adding a catch-up vaccination component to the girl vaccination. Adding a catch-up component
decreases cervical cancer in earlier stage compared to adding a boy vaccination component
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is no longer than 10 years, 5) DALYs are not dis-
counted, and 6) the discount rate is 5 % for DALYs and
6 % for the costs.
Moreover, the predicted cost-effectiveness was influ-
enced by the time horizon. If the time horizon is re-
duced to 30 years then the strategy of adding a boy
vaccination and catch-up component for both females
and males aged 11–25 years old is predicted to become
cost-effective (Additional file 1).
The model predicts that the cost-effectiveness of
HPV vaccination is not affected by different initial ages
of girl vaccination. When taking into account all cer-
vical cancer cases, we find that the number of cancers
due to other high-risk HPV increases by about 2 %
from the baseline. However, this does not change the
cost-effectiveness results (Additional file 1).
To evaluate the generalizability of results, we cali-
brated the model to different populations in terms of
population size and demographic structure, i.e. Vientiane
province. The results were robust to these changes
(Additional file 1).
Discussion
Our model suggests that vaccinating 10-year-old girls
is very cost-effective even if the vaccine is expensive
(I$ 100 per dose). Adding a boy vaccination compo-
nent produces little additional benefit, with a further
reduction in cervical cancers of just of 3.4 %. As a re-
sult, adding this component is less effective than a girl
vaccination along with a catch-up vaccination compo-
nent for 11–25 year-old women, which results in a fur-
ther reduction of 8.9 % in the number of cancers and
an additional diminution of 5 DALYs per 1000 women.
This catch-up vaccination component becomes the
most attractive strategy with a cost per DALY below
one GDP per capita. This result is similar to that
found in a previous review [17].
Moreover, the model predicts that adding a catch-up
component for females aged 11–25 years old is more at-
tractive than adding a catch-up component for an older
age group, if GDP per capita is considered. This age
group was also found to be cost-effective in the studies
of Elbasha and colleagues [18] and Dasbach colleagues
[19]. However, to provide more comprehensive informa-
tion regarding the appropriate maximum limit age in the
catch-up component, which was not reported in previ-
ous studies [19], we compared further maximum ages,
from 18 to 75, using 5-year intervals. Our study found
that a catch-up component for women up to 40 years
old was the most attractive option, costing less than one
GDP per capita per DALY averted. Several reasons can
be proposed. First, the ideal age for a catch-up compo-
nent might depend on sexual behavior. Second, the
prevalence of HPV infection in our model simultan-
eously decreases after 40 years of age. Finally, one should
consider that the incidence of cervical cancer increases
after 40 years of age. However, our results should be
interpreted cautiously because our model was not
Table 4 The cost-effectiveness of catch-up vaccination by upper age limit








1. No vaccination with current screening 4497 - - -
2. Catch-up 11–18 24,680 34.1 591.9 592
3. Catch-up 11–20 25,548 34.4 611.9 2373
4. Catch-up 11–22 26,446 34.7 632.5 3476
5. Catch-up 11–25 27,807 35.1 664.1 3420
6. Catch-up 11–30 29,983 35.7 713.9 3880
7. Catch-up 11–35 31,919 36.2 757.5 3882
8. Catch-up 11–40 33,584 36.5 796.9 4662
9. Catch-up 11–45 34,991 36.7 830.9 7012
10. Catch-up 11–50 36,159 36.9 858.0 8408
11. Catch-up 11–55 37,109 36.9 883.8 D
12. Catch-up 11–60 37,857 37 901.6 15,750
13. Catch-up 11–65 38,418 37 916.8 D
14. Catch-up 11–70 38,812 37 927.4 D
15. Catch-up 11–75 39,059 37 934.1 D
Note: The cost-effectiveness ratio was a comparison of an option and the baseline scenarios (no vaccination with current screening). The incremental cost of the
effectiveness ratio expressed as DALY averted is listed in order of increasing cost. In non-dominant strategies, the ICER was calculated by dividing different costs
by different effectiveness. The intervention was compared to the next more effective and more costly option. The D refers to strong dominance, which is
expressed as a higher cost and a lower effectiveness compared to the alternative options. The currency is 2013 international dollars, using purchasing power parity
The GDP per capita in 2013 was about 4822 international dollars [30]
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calibrated to age-specific HPV prevalence, although the
trend of HPV prevalence in Lao PDR seems to be similar
to that found worldwide [20]. Also, a clinical trial
showed that the vaccine was safe and that it conferred a
high-level of immunogenicity in women up to the age of
45 years [21].
Nevertheless, in the case of a higher burden of the dis-
ease, or waning of natural immunity, or a suboptimal
protection from the vaccine in terms of duration, effect-
iveness, or vaccination coverage, implementing a catch-
up component for females aged 11–75 years old is the
most attractive option. This parameter’s influence was
also reported by Jit and colleagues [6] and by Van de
Velde and colleagues [22]. Indeed, the effectiveness of
the vaccination increases when 1) the incidence of cer-
vical cancer is high or 2) the natural immunity wanes;
contrarily, this effectiveness decreases in other cases.
However, both situations lead to the same conclusion,
which is that it is more efficient to vaccinate larger fe-
male populations. The lower effectiveness of vaccines
might be true in developing countries due to the fact
that the HPV vaccine also requires an appropriate main-
tenance and delivery process [23]. In Lao PDR, a low op-
timal efficacy of vaccination was reported for hepatitis B
vaccine, at only around 65 %. The rate is even lower still
in rural areas [24]. Moreover, a low vaccination coverage
might be found in rural settings where fewer girls have
been found to attend school regularly [8].
Furthermore, it is more cost-effective to include a
boy vaccination component in addition to the catch-up
component to the girl vaccination program if the time
covered by the simulation is shorter, 30 years for in-
stance. This reflects the insufficient level of vaccination
protection in the population in the early stages of
implementation.
Our study had some limitations. First, our model did
not take into account any cross-protection provided by
the vaccine to other HPV-related diseases, such as warts
and other cancers. This might underestimate the total
DALYs averted related to all HPV types. However, this
might not significantly bias our conclusion because of
the slight benefits provided by this cross-protection [25].
Second, we have ignored some items related to screening
and treatment. These include the cost of specimen deliv-
ery and the cost of treatment complications. This might
lead to an underestimation of the total cost per person.
However, according to Goldhaber-Fiebert and Goldie
[26], these cost components are small relative to the cost
of screening and treatment. Third, it is likely that newer
vaccines, active against multiple HPV types, will provide
even greater levels of protection [27]. It has also been re-
ported that two doses of HPV vaccine are equally effect-
ive in producing immunity as three doses [28]. This
might further reduce the cost, and subsequently increase
the cost-effectiveness of the vaccination, as demon-
strated in a cost-effectiveness study in the UK [29], As
our study did not take into account these aspects,
future studies might be necessary to investigate these
factors for Lao PDR. Finally, DALYs as the outcome of
interest might be less interpretable compared to
Quality-Adjusted Life Years (QALYs), because they do
not reflect as precisely sociocultural considerations re-
garding health states. Moreover, the discounting rate
used for DALY is controversial because it leads to age
discrimination. However, there is no valid instrument
to measure utilities in the Lao population. A standard
gamble method was tried out to produce utilities scores
for a range of health problems in a sample of Lao stu-
dents, but could not come out with sensible results
(Daniel Reinharz, personal communication). That is
why DALYs were used as recommended by WHO [15].
Finally, one should stress that the study does not re-
flect the financial affordability of the health care system
in Lao PDR. The threshold ratio used to measure the
cost-effectiveness is the GDP per capita, which is contro-
versial. Moreover, the limited resources in the country
lead to strong competition among interventions in
health care programmes. Accurate data on the burden of
this disease in Lao PDR would provide important infor-
mation for decision makers.
Conclusions
Vaccinating 10-year-old girls with a catch-up program
component for 11–25 year-old women is the most at-
tractive option for Lao PDR in 100 years. The girl HPV
vaccination, in combination with a catch-up component,
should at least be considered for nationwide implemen-
tation in Lao PDR.
Additional file
Additional file 1: Detailed methods and results for economic
evaluation. (DOCX 6847 kb)
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